L-arginine

Generic Name: L-arginine

Brand Names: Clinimix 2.75/5

Drug Type: Small Molecule

CAS Number: 74-79-3

Clinical Trials

Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study

Phase 4

Completed

Conditions: Erectile Dysfunctions

Interventions: Drug: L-Arginine
Drug: Tadalafil 5 mg

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Fayoum University Hospital

Target Recruit Count: 180

Registration Number: NCT06947265

Locations: 🇪🇬
Mohamed Mahmoud Dogha, Fayoum, Keman Fares, Egypt

The Role of L-arginine in Polycystic Ovary Syndrome

Not Applicable

Not yet recruiting

Conditions: Polycystic Ovary Syndrome
L-arginine
Gut Microbiome

Interventions: Drug: L-arginine intervention

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: Shanghai 10th People's Hospital

Target Recruit Count: 100

Registration Number: NCT06728644

Locations: 🇨🇳
Department of Endocrinology, Shanghai Tenth People's Hospital, Shanghai, China

Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

Phase 3

Not yet recruiting

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Chromium
Drug: Myoinositol
Drug: l-arginine
Drug: Letrozole 2.5mg

First Posted Date: 2024-05-08

Last Posted Date: 2024-05-08

Lead Sponsor: Beni-Suef University

Target Recruit Count: 100

Registration Number: NCT06405243

Locations: 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Egypt
🇪🇬
Beni-suef university, Banī Suwayf, Egypt

Association Between Postoperative Administration of L-Arginine and CSA-AKI

Recruiting

Conditions: Acute Kidney Injury

Interventions: Drug: L-Arginine hydrochloride

First Posted Date: 2024-02-08

Last Posted Date: 2025-04-04

Lead Sponsor: Xijing Hospital

Target Recruit Count: 7000

Registration Number: NCT06248359

Locations: 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China

Evaluation of the Effect of Liposomal L-Arg and Vit C Integration on Mitochondrial Function in Patients With Heart Failure

Phase 3

Recruiting

Conditions: Heart Failure

Interventions: Drug: L-arginine and liposomal vitamin C

First Posted Date: 2023-09-21

Last Posted Date: 2024-04-22

Lead Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Target Recruit Count: 56

Registration Number: NCT06044194

Locations: 🇮🇹
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Lombardia, Italy

Effect of the Administration of L-arginine vs. Placebo in Patients Diagnosed With Presbyvestibulopathy.

Phase 2

Withdrawn

Conditions: Presbyvestibulopathy

Interventions: Other: Placebo
Drug: L-arginine

First Posted Date: 2023-07-06

Last Posted Date: 2024-02-15

Lead Sponsor: Centro Universitario de Tonalá

Registration Number: NCT05932979

Locations: 🇲🇽
CUTonalá, Tonalá, Jalisco, Mexico

L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

Phase 3

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: L-Arginine

First Posted Date: 2022-07-22

Last Posted Date: 2023-11-21

Lead Sponsor: Tanta University

Target Recruit Count: 50

Registration Number: NCT05470998

Locations: 🇪🇬
Tanta university, Tanta, Other (Non U.s.), Egypt

Immunonutrition for Diabetic Foot Ulcers

Phase 2

Terminated

Conditions: Diabetes Mellitus
Diabetic Peripheral Neuropathy
Diabetic Foot Ulcer

Interventions: Drug: Lovaza
Drug: L-Arginine Powder
Drug: Vitamin C

First Posted Date: 2022-03-16

Last Posted Date: 2024-12-27

Lead Sponsor: Prisma Health-Midlands

Target Recruit Count: 1

Registration Number: NCT05281562

Locations: 🇺🇸
Prisma Health, Columbia, South Carolina, United States

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

Phase 3

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: L-Arginine Hydrochloride
Other: Normal saline

First Posted Date: 2021-04-09

Last Posted Date: 2025-04-02

Lead Sponsor: Claudia R. Morris

Target Recruit Count: 271

Registration Number: NCT04839354

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta at Hughes Spalding, Atlanta, Georgia, United States

and more 7 locations

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

Phase 1

Recruiting

Conditions: Peripheral Artery Disease
Claudication, Intermittent
Peripheral Vascular Diseases

Interventions: Drug: Tetrahydrobiopterin 10 mg/kg
Drug: Tetrahydrobiopterin 20 mg/kg
Drug: L-Ascorbate
Drug: L-Arginine

First Posted Date: 2021-03-16

Last Posted Date: 2025-04-06

Lead Sponsor: Louis Messina

Target Recruit Count: 10

Registration Number: NCT04800692

Locations: 🇺🇸
UMASS Memorial Healthcare - University Campus, Worcester, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy